Stilla Technologies Signs Put Option with Bio-Rad
Deal News | Feb 18, 2025 | Goodwin
Stilla Technologies, a start-up known for high-precision genetic analysis, has signed a put option agreement for its acquisition by Bio-Rad Laboratories, a leading company in life science research and clinical diagnostics. The transaction, advised by Goodwin, is expected to close in the third quarter of 2025, pending regulatory approvals and consultation with employee representative bodies. This acquisition will enable Bio-Rad to enhance its capabilities in applied research and clinical diagnostics, thereby addressing the growing demand for digital PCR applications, crucial for genomics and applied sciences. Stilla Technologies was founded in 2013 and is recognized for its cutting-edge digital PCR solutions, incorporating advanced technology from cole Polytechnique to aid cancer monitoring.
Sectors
- Life Sciences
- Genomics
- Clinical Diagnostics
Geography
- France – Stilla Technologies is based in France, which is central to its involvement in the acquisition process.
- United States – Bio-Rad Laboratories, the acquiring company, is headquartered in the United States, making it a significant geography for the deal.
Industry
- Life Sciences – The article revolves around Life Sciences, given that Stilla Technologies specializes in genetic analysis, and its acquisition by Bio-Rad enhances strategic growth within this field.
- Genomics – The transaction involves entities working in genomics, focusing on digital PCR technology, a key tool in genomics research and diagnostics.
- Clinical Diagnostics – Bio-Rad's expansion into applied research and diagnostics suggests relevance to the Clinical Diagnostics industry.
Financials
- Not disclosed – The deal's financial details, including the acquisition price, were not disclosed in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Stilla Technologies | Target Company | Company | Stilla Technologies is a start-up specializing in high-precision genetic analysis solutions using digital PCR technology. |
| Bio-Rad Laboratories | Bidding Company | Company | Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics products. |
| Goodwin | Legal Advisor | Company | Goodwin is the legal advisor to Stilla Technologies and the sellers in this acquisition. |